Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

The "Cellular Starting Materials Market by Product, by Grade, by End-User, and By Region" report has been added to ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.

William Blair downgraded Charles River (CRL) to Market Perform from Outperform without a price target “There is simply too much working ...

A February meeting could bring about the end of the trade in macaque monkeys commonly used in medical research.

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Charles River Laboratories International, Inc. today announced the launch of Apollotm for CRADL®, a secure cloud-based platform that enhances leading vivarium rental services through a digital ...

Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...

Equities research analysts at William Blair reduced their FY2025 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a report issued on Wednesday, January 15th ...

UBS Group reaffirmed their neutral rating on shares of Charles River Laboratories International (NYSE:CRL – Free Report) in a research note released on Friday morning, MarketBeat reports. They ...